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Magnetic resonance measurements of renal blood flow as a
marker of disease severity in autosomal-dominant polycystic
kidney disease.
Background. Autosomal-dominant polycystic kidney disease
(ADPKD) is an inherited disorder characterized by renal cyst
growth, early development of hypertension, and late occurrence
of renal insufficiency. Despite evidence for the importance of
nephroangiosclerosis in the progression of renal insufficiency in
ADPKD, evaluation of renal blood flow (RBF) as a surrogate
marker of disease severity has received little attention.
Methods. Flow phantoms and repeat RBF measurements
assessed accuracy and reproducibility. One hundred twenty-
seven ADPKD subjects with creatinine clearances >70 mL/min
underwent measurements of RBF, total, and cyst renal vol-
umes, and % cyst volumes by magnetic resonance (MR) and
of glomerular filtration rate (GFR). Renal vascular resistance
(RVR) was calculated. MR blood flow sequences utilized a two-
dimensional cine phase-contrast breath-hold pulse sequence
perpendicular to the renal arteries. Flow rates were calculated
utilizing FLOW software. Volumetric analysis was performed
using stereology and region-based thresholding.
Results. Excellent accuracy and intraobserver and in-
terobserver reproducibility were demonstrated. Anatomic
(total kidney volume, total cyst volume, and % cyst vol-
ume), hemodynamic (RBF and RVR), and functional (GFR)
parameters were strongly correlated. Left polycystic kidneys
were larger and had more severe disease. Regression analysis
showed that age, diagnosis of hypertension, anatomic parame-
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ters and hemodynamic parameters were significant predictors
of GFR. Multiple linear regression analysis identified age and
hemodynamic parameters only as separate predictors of GFR.
Anatomic, hemodynamic, and functional parameters discrimi-
nated between normotensive and hypertensive subjects despite
antihypertensive treatments.
Conclusion. Renal hemodynamic parameters measured by
MR correlate with anatomic and functional indices of disease
severity, are the strongest predictors of renal function, and
deserve further consideration as an outcome measure in clinical
trials to guide therapy in ADPKD.
Autosomal-dominant polycystic kidney disease
(ADPKD) is an inherited disorder characterized by renal
cyst growth, early development of hypertension, and late
occurrence of renal insufficiency [1]. A reduction in renal
blood flow (RBF) occurs early and may precede the
development of hypertension [2] or be found in its early
stages [3–5]. Activation of the renin-angiotensin system
(RAS) [2–7], increased sympathetic nerve activity [8],
enhanced generation of endothelin [9–11], and impaired
production of nitric oxide [12] may all contribute to renal
vasoconstriction, remodeling of the microcirculation,
and development of renal insufficiency. Administration
of angiotensin I-converting enzyme (ACE) inhibitors
to patients with normal renal function corrects only
partially the reduction in RBF [3–5]. This indicates that
the blockade of the RAS is not complete, that other
vasoconstrictors are involved, or that fixed structural
changes are already present at early stages of the disease.
Ritter and Barhr [13] demonstrated in 1929 that the
number of small arteries and arterioles was greatly re-
duced in polycystic kidneys. Schacht [14, 15] in 1930 and
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1931 noted marked thickening of the media and increased
wall-to-lumen ratio in small arteries and arterioles of
polycystic kidneys. More recent microangiographic [16]
and histopathologic studies [17] have confirmed these
observations. The presence of severe nephroangioscle-
rosis and global glomerulosclerosis and the absence of
glomerular hypertrophy and segmental glomerulosclero-
sis are consistent with a major role for ischemia in the
progression of renal insufficiency in ADPKD.
The evaluation of RBF in ADPKD has received lit-
tle attention. The few studies in this area have used
measurements that rely on renal clearances of para-
aminohippurate [2–5]. These assume a normal renal
extraction [18], not likely in ADPKD. Recent improve-
ments in magnetic resonance (MR) technology now allow
precise direct determinations of RBF with single breath-
hold MR acquisitions [19].
The National Institutes of Health (NIH)-sponsored
Consortium for Radiologic Imaging Studies of Polycys-
tic Kidney Disease (CRISP) was created to develop
innovative imaging techniques and analyses to follow dis-
ease progression or to evaluate treatments for ADPKD.
A goal was to determine whether MR measurements
of RBF can be used as a surrogate marker of disease
progression. Here, we present the results obtained at
the baseline visit and correlate the renal hemodynamic
parameters with other clinical, anatomic, and functional
indices of disease severity.
METHODS
Study organization
CRISP clinical centers included the Mayo Foundation
and University of Alabama at Birmingham as a single
center, Emory University, and University of Kansas
Medical Center. Washington University served as the
data coordinating and image analysis center (DCIAC).
The DCIAC collected images transferred from the col-
laborating institutions in Digital Imaging and Commu-
nications in Medicine (DICOM) format, segmented and
analyzed the images, stored and recorded the results us-
ing a state-of-the-art Web-based system, and performed
statistical analysis. MR determinations of RBF were per-
formed only at the Mayo Foundation and Emory Univer-
sity. MR studies were performed on a Signa CV/I 1.5T
scanner (GE Medical Systems, Milwaukee, WI, USA) at
the Mayo Foundation and on a Gyroscan Intera 1.5 T
scanner (Philips Medical Systems, Best, The Netherlands)
at Emory University.
Validation studies for MR flow measurement
A polyvinyl alcohol (PVA) phantom was used to val-
idate steady flow measurements by MR imaging. PVA
is material with a solid gel consistency, sufficiently firm
to attach to a flow loop system. It contains free protons
to yield a nonzero MR imaging signal, simulating vessel
lumen in in vivo studies [20]. A block of PVA was con-
structed with six circular channels with diameters ranging
3.18 to 11.25 mm (range of adult human renal artery inter-
nal diameters). A 60:40 water/glycerin mixture was used
to simulate blood viscosity. Measurements were obtained
at flow rates that correspond with values from the litera-
ture for renal arterial blood flow (200 to 1200 mL/min),
using the clinical MR protocol described below [21].
Cardiac triggering of the MR acquisition was performed
using built-in physiology simulation software. True flow
was determined by weighing the return from the phan-
tom flow loop over a 1-minute interval. A second pulsatile
flow phantom was designed to evaluate MR measure-
ments of dynamic flow. It consisted of a standard cardiac
pump device to create pulsatile flow through clear plas-
tic tubings measuring 5 mm (main renal artery) or 2 mm
(small accessory artery) in diameter. It used tap water
as flow medium and simulated systolic and diastolic ve-
locity variations with average flow rates of 540, 315, and
145 mL/min. Flows were measured three times in each
tube at different flow rates.
Reproducibility was evaluated through blinded re-
peated analysis of renal arterial flow data sets from
patients with single renal arteries.
Study protocol
ADPKD subjects were eligible for enrollment if they
were older than 15 years of age and younger than 46 years
of age and had a measured or estimated creatinine clear-
ance >70 mL/min. ADPKD was defined by the criteria
of Ravine et al [22]. Subjects were ineligible if they had
undergone renal surgery, had cyst drainage procedures,
were unable to undergo breath-hold MR imaging or had
other medical conditions potentially affecting renal func-
tion. Hypertension was defined as a previous diagnosis
and current use of antihypertensive medications or as
systolic and diastolic blood pressures >140/90 mm Hg on
three consecutive visits.
Enrolled subjects were scheduled for a 2-day evalua-
tion in the General Clinical Research Center after sign-
ing an informed written consent. They were instructed
to continue their medications, to discontinue any nons-
teroidal anti-inflammatory medications for at least 7 days
prior to evaluation, and not to initiate diuretic therapy
within 14 days of evaluation. During the day prior to
admission, subjects collected a 24-hour urine sample for
determination of creatinine, sodium, and albumin excre-
tions. Weight and height were measured at admission.
Blood pressures were measured in the morning, prior
to antihypertensive medication intake, in the left and
right arms after being seated for at least 5 minutes on
three occasions 3 minutes apart using an oscillometric
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Fig. 1. Magnetic resonance (MR) angiogram
of the renal arteries in a patient with
autosomal-dominant polycystic kidney dis-
ease (ADPKD). (A) Following the MR an-
giogram a flow acquisition MR pulse sequence
(see Methods section for detailed description)
is performed perpendicular to the renal artery.
(B) The flow acquisition pulse sequence yields
a set of cross-sectional images through the
renal arteries and veins. Flow analysis is
performed on the MR signal information con-
tained within the renal artery.
measuring device. Blood was obtained prior to glomeru-
lar filtration rate (GFR) studies for the determination of
blood hemoglobin, serum electrolytes, liver enzymes, and
lipid profiles using standard laboratory techniques. GFR
was measured by a nonradiolabeled iothalamate clear-
ance technique with sonographic monitoring of bladder
emptying [23, 24].
MR imaging
Studies were in the morning prior to medication intake
and breakfast. A 20-gauge intravenous angiocatheter was
kept open with normal saline solution. Electrocardio-
graphic pads or a peripheral gating pulsometer were
positioned for ECG gating. A phased-array surface coil
was positioned with its center over the inferior costal mar-
gin. An initial spoiled gradient echo scan and sequence
was performed to localize the kidneys. Breath-hold
coronal T2-weighted images (SSFSE/HASTE) with fat
saturation were obtained with 3 and 9 mm fixed slice
thickness, as well as an adjusted slice thickness attained
with a single breath-hold. Neighboring image groups, nec-
essary to cover the entire kidney, were overlapped by one
slice. Coronal T1-weighted images (three-dimensional
TFE/FMPSPGR), without fat saturation, with 3 mm fixed
slice thickness, were obtained. Then, a three-dimensional
gadolinium-enhanced (1 mL/sec for a total of 20 to 30 mL,
0.1 mmol/kg) MR angiography was performed using a
standard fast-spoiled gradient echo sequence. A delay
between injection and initiation of MR angiography se-
quence was chosen to ensure that central lines of K
space were acquired during peak arterial enhancement.
Coronal T1-weighted images of the kidneys were re-
peated at 120 to 180 seconds after beginning of the
injection.
Measurements of RBF by MR imaging
Thick section oblique axial two-dimensional phase-
contrast breath-hold MR angiograms were obtained
along the course of each renal artery and acted as ref-
erence images (Fig. 1). The MR flow measurements
were obtained perpendicular to the oblique axial two-
dimensional reference images of the renal arteries utiliz-
ing a cardiac-gated, two-dimensional, fast gradient echo,
phase-contrast pulse sequence. MR blood flow pulse se-
quence parameters were TR = 8 to 10 msec, TE = 3
to 5 msec, FOV = 14 to 20 cm, flip angle = 20 degrees,
5 mm slice thickness, 224 to 256 phase encodings, one ex-
citation, 18-second scan time, with retrospective cardiac
gating and flow compensation at 20 phases of the cardiac
cycle (General Electric) or TR = 18 to 36 msec, TE =
8 to 16 msec, FOV = 20 cm, flip angle = 35 degrees,
5 mm slice thickness, 160 to 224 phase encodings, one
excitation, 20- to 27-second scan time, with cardiac gat-
ing at 12 phases of the cardiac cycle (Philips). Velocity
encoding value was 100 cm/sec and flow acquisition was
obtained in the slice direction. Flow analysis was per-
formed utilizing FLOW software (Medis, Inc., Leiden,
The Netherlands). Semiautomated or manual techniques
were employed for definition of the vessel borders in the
flow images depending on image quality. Vessel area es-
timations were made in images at all phases of the car-
diac cycle. Average maximal and minimal cross-sectional
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vessel areas, peak systolic and end diastolic velocities, and
flow values for each renal artery were measured. Renal
vascular resistance (RVR) and resistive index (RI) were
calculated using accepted formulas [25, 26].
Cyst and renal volume measurements
Kidney volumes were measured from T1-weighted
images using stereology [27] and renal cyst volumes
from T2-weighted images using region-based threshold-
ing. The reliability and reproducibility of these techniques
in ADPKD are described in detail elsewhere [28]. Stere-
ology is a method of segmenting an object by counting
the number of intersections of a randomly oriented and
positioned grid over the object. Region-based threshold-
ing utilizes an interactive selection of a threshold by an
analyst using T2-weighted images. Cysts are brighter than
the renal parenchyma in T2-weighted images and are seg-
mented from voxels with intensity values greater than the
threshold. Total kidney and cyst volumes were calculated
from sets of contiguous images by summing the products
of the area measurements and the slice thickness. Percent
cyst volume was determined from the ratio of cyst volume
to renal volume [29–32].
Statistical methods
The data were examined using SAS system software
(SAS Institute, Inc., Cary, NC, USA 2002). Percent er-
rors for phantom MR flow measurements were calculated
and expressed as mean ± SD for each condition [33].
MR flow studies of 127 patients were included in com-
putations. Comparisons between groups were performed
using t tests. Comparisons within persons (right vs. left)
were performed using dependent-samples t tests. Corre-
lations were computed as Pearson r values. Regression
analyses are simple linear regressions.
RESULTS
Phantom and reproducibility studies
Steady-flow measurements with the PVA showed that
accuracy was strongly related to the phase-encoding
pixel resolution. Correlation coefficients (R2) for true/
measured flow ranged from 0.77 (350 mm FOV, 96 views,
pixel resolution 3.6 mm) to 0.99 (160 mm FOV, 192 views,
pixel resolution 0.83 mm). Relative measurement errors
for a range of vessel sizes of 0.8 to 3.8 pixels, averaged
across flow rates, ranged from 112% down to 1.55%.
Measurement errors below 10% were reliably obtained in
phantom experiments with 200 mm FOV and 192 or more
phase-encoding views per image. Pulsatile-flow measure-
ments were performed three times and averaged by each
of two radiologists. The actual and estimated flow rates
and the percent error of the estimated flow rates for dif-
ferent tubing sizes and FOVs are summarized in Table 1.
Table 1. Accuracy of renal blood flow magnetic resonance (MR)
measurements by two radiologists using a flow phantom
Tubing Field of Actual flow Estimated flow Error
size mm view cm rate mL/min rate mL/min %
5 14 315 313,322 0.6–2.2
5 14 540 545,530 0.9–1.9
5 20 315 313,311 0.6–1.2
5 20 540 554,562 2.8–4.1
2 14 145 134,125 7.6–13.8
2 20 145 143,149 1.4–2.8
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Fig. 2. Analyses of patient with autosomal-dominant polycystic kidney
disease (ADPKD). (A) Velocity, cross-sectional area, and blood flow
plotted during 20 phases of the cardiac cycle in the left renal artery in a
magnetic resonance (MR) flow acquisition of an ADPKD patient. (B)
Cross-sectional flow acquisition images in the left renal artery of the
same patient.
These showed 0.6% to 4.1% errors of estimated flow
rates, using 14 or 20 cm FOVs, for a 5 mm tubing and
actual flow rates of 315 or 540 mL/min, and 1.4% to
13.8% errors for a 2 mm tubing and actual flow rates of
145 mL/min.
Based on the results of the phantom studies, MR renal
blood flow acquisitions were optimized in patients utiliz-
ing a FOV of 20 cm or less and at least 192 phase-encoding
steps. A representative sample of data recorded during
the cardiac cycle is illustrated in Figure 2. The average
intrareviewer coefficient of variation (CV) of total RBF
measurements performed three times by two radiologists
in 19 patients (Fig. 3) was 1.4% for reviewer A and 1.2%
for reviewer B. The estimated reliability (intraclass cor-
relation coefficient) for reviewer A was 0.987 and 0.983
for reviewer B. Using within patient replication means,
the average interreviewer CV was 2.5% with a reliability
coefficient of 0.983.
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Fig. 2. (Continued).
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Fig. 3. Blood flow measurements repeated three times in 19 autosomal-dominant polycystic kidney disease (ADPKD) patients by radiologists A
and B. The intrareviewer coefficients of variation were 1.2% and 1.4%. The average interreviewer coefficient of variation was 2.5%.
Description of anatomic, hemodynamic,
and functional data
The 127 subjects in the study, 46 male and 81 female,
had an age of 32.9 ± 8.2 years, a mean arterial pressure
of 96.3 ± 10.8 mm Hg, and an iothalamate clearance
of 99.1 ± 23.0 mL/min/1.73 m2. Forty of them (31.5%)
had multiple renal arteries, bilaterally in six and uni-
laterally in the rest. Women had lower systolic blood
pressures, hematocrits, serum concentrations of creati-
nine and triglycerides, and urine sodium excretions, and
higher serum concentration of high-density lipoprotein
(HDL) cholesterol than men. Right and left renal vol-
umes and hemodynamic parameters are compared in
Table 2. Left kidneys were larger than right kidneys
and had more severe disease. RBF and peak systolic
and end diastolic velocities were lower and RVR was
higher in the left kidneys, while RI was similar in both
kidneys.
Table 2. Comparison of right and left renal volumes and
hemodynamic parameters (N = 127)
Right Left P value
Kidney volume mL 498.4 ± 309.5 554.5 ± 344.3 <0.001
Cyst volume mL 234.4 ± 230.9 275.4 ± 272.6 0.001
% Cyst volume 38.3 ± 18.4 40.5 ± 18.6 0.047
Renal blood flow 398.5 ± 124.4 354.7 ± 125.9 <0.001
mL/min/1.73 m2
Peak systolic velocity 38.4 ± 11.7 31.7 ± 9.3 <0.001
cm/sec
End diastolic velocity 14.3 ± 6.0 11.9 ± 7.1 <0.001
cm/sec
Renal vascular resistance 21332 ± 7750 25164 ± 11662 <0.001
dynes sec.cm−5
Resistive index 0.63 ± 0.11 0.62 ± 0.18 NS
Correlations between total or ipsilateral kidney
volumes and renal hemodynamic parameters
These correlations are summarized in Table 3. Total
kidney volume, total cyst volume, and % cyst volume
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Table 3. Correlations of total or ipsilateral kidney volumes with
functional or hemodynamic parameters
Kidney volume Cyst volume % Cyst volume
r p r p r P
Age 0.388 <0.001 0.392 <0.001 0.434 <0.001
Mean arterial 0.284 0.001 0.276 0.003 0.259 0.023
pressure
Both kidneys
Iothalamate −0.314 <0.001 −0.330 <0.001 −0.368 <0.001
clearance
Blood flow −0.344 <0.001 −0.377 <0.001 −0.434 <0.001
Vascular 0.450 <0.001 0.467 <0.001 0.482 <0.001
resistance
Right kidney
Blood flow −0.241 0.006 −0.267 0.002 −0.353 <0.001
Peak systolic −0.167 0.057 −0.199 0.028 −0.197 0.043
velocity
End diastolic −0.247 0.005 −0.297 <0.001 −0.318 0.001
velocity
Vascular 0.339 <0.001 0.351 <0.001 0.419 <0.001
resistance
Resistive index 0.219 0.013 0.262 0.003 0.274 0.002
Left kidney
Blood flow −0.382 <0.001 −0.428 <0.001 −0.439 <0.001
Peak systolic −0.182 0.042 −0.190 0.050 0.129 NS
velocity
End diastolic −0.261 0.003 −0.279 0.002 −0.336 <0.001
velocity
Vascular 0.541 <0.001 0.584 <0.001 0.500 <0.001
resistance
Resistive index 0.227 0.011 0.246 0.008 0.327 <0.001
correlated positively with age, blood pressure, and RVR,
and negatively with GFR and RBF. Right and left kidney
volumes, cyst volumes, and percent cyst volumes were
inversely correlated with the ipsilateral RBF and end
diastolic velocity and positively correlated with RVR and
RI.
RBF as a predictor of GFR
Iothalamate clearances were significantly higher in
normotensive than hypertensive subjects (see below).
In addition, they were inversely correlated with age
(r = −0.390, P < 0.001) and kidney volume (see
above) and positively correlated with RBF (r = 0.5172,
P < 0.001). The regression analysis shown in Table 4 uses
age, gender, diagnosis of hypertension, kidney volume,
and RBF to predict GFR. When considered alone (as
measured by the Pearson correlation r), age, diagnosis of
hypertension, kidney volume, and RBF were all signifi-
cant predictors. In the multiple-variable model, however,
only age and RBF were significant independent predic-
tors. The R2 value of 0.3417 was relatively large. If r for
RBF in the univariate analysis (0.5172) is squared, the
ratio 0.51722/0.3417 = 0.783. Therefore, RBF alone ac-
counted for almost 80% of the variance in the model.
Both GFR and RBF were corrected for body surface area
(BSA). To ensure that this correction was not inducing a
relationship, uncorrected versions of these variables were
used. The results were almost exactly the same, with R2 =
Table 4. Regression model predicting glomerular filtration rate
(GFR): Effect of age, gender, physical kidney measures, and renal
blood flow
Source F Value P value r value P value
Age 6.16 0.0145 −0.3948 0.0001
Gender 2.37 0.1260 0.0733 0.3894
Diagnosis of hypertension 0.11 0.7394 −0.1883 0.0347
Total kidney volume 0.50 0.4827 −0.2918 0.0014
Total corrected renal blood 27.80 <0.0001 0.5172 0.0001
flow
0.346 and the same significant variables. Similar results
were obtained if RBF was replaced by RVR or if total
kidney volume was replaced by total cyst volume or per-
cent cyst volume.
Total kidney and cyst volumes and renal hemodynamic
parameters in hypertensive and normotensive subjects
and effects of treatment
These parameters are presented in Table 5. Hyper-
tensive had significantly higher RVR than normoten-
sive subjects. Of the 74 patients with hypertension, 52
were treated with ACE inhibitors or angiotensin recep-
tor blockers, eight with beta blockers, seven with calcium
channel blockers, and eight with diuretics. The subjects
treated with ACE inhibitors/angiotensin receptor block-
ers had significantly lower mean arterial pressures and
those treated with calcium channel blockers significantly
higher pulse pressures than those not taking these med-
ications. There was a statistically nonsignificant trend
toward higher RBF and GFR in the subjects treated with
ACE inhibitors/angiotensin receptor blockers or with cal-
cium channel blockers, whereas the reverse was true for
those taking beta blockers or diuretics.
DISCUSSION
The results of the present study demonstrate that
breath-hold gradient-echo techniques used with current
imaging equipment provide adequate resolution for ac-
curate measurements of RBF in phantoms simulating
renal artery hemodynamics and for reproducible mea-
surements of RBF in patients with ADPKD. Using
this technology, we studied 127 CRISP participants and
demonstrated that renal hemodynamic parameters mea-
sured by MR are significantly correlated with anatomic
and functional indices of disease severity. Age, diagno-
sis of hypertension, total kidney, total cyst, and percent
cyst volumes, RBF and RVR were significantly correlated
with GFR. The regression analysis, however, indicated
that age and renal hemodynamic parameters (RBF and
RVR), but not kidney volumes, were independent pre-
dictors of GFR. These results strongly suggest that RBF
and RVR measured by MR deserve further consideration
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Table 5. Total kidney volumes and renal hemodynamic parameters in normotensive compared to hypertensive subjects and effects of
antihypertensive medications
Mean Systolic blood Renal Renal vascular Glomerular
Total arterial pressure-diastolic blood resistance filtration
Blood Age kidney pressure blood pressure flow mL/min/ dynes rate mL/
pressure Number years volume mL mm Hg mm Hg 1.73 m2 sec.cm−5 min/1.73 m2
Normotensive 53 29.2 ± 7.7 731 ± 406 91.7 ± 9.4 38.8 ± 7.2 783 ± 205 9965 ± 2646 104.2 ± 19.2
Hypertensive 74 34.5 ± 7.6 1284 ± 673 99.6 ± 10.6 38.6 ± 8.3 732 ± 243 12135 ± 4383 95.5 ± 24.9
P value <0.001 <0.001 <0.001 NS NS 0.002 0.035
On ACE inhibitors/ARBa 52 35.5 ± 8.2 1343 ± 726 97.0 ± 10.4 38.3 ± 6.3 746 ± 258 11701 ± 4502 97.8 ± 24.8
Without ACE inhibitors/ARBa 22 35.0 ± 6.2 1143 ± 516 105.8 ± 8.5 39.5 ± 12.1 699 ± 206 13160 ± 3997 89.9 ± 24.9
P value NS NS <0.001 NS NS NS NS
On calcium channel blockersa 7 29.2 ± 8.6 779 ± 236 100.5 ± 9.2 47.1 ± 8.9 823 ± 226 10415 ± 2889 112.0 ± 31.0
Without calcium channel 67 36.0 ± 7.3 1336 ± 683 99.6 ± 10.8 37.8 ± 7.8 722 ± 245 12314 ± 4488 93.7 ± 23.8
blockersa
P value 0.022 0.040 NS 0.004 NS NS NS
On beta blockersa 8 36.8 ± 8.0 1177 ± 370 102.8 ± 6.2 38.2 ± 8.1 594 ± 132 14404 ± 3175 84.4 ± 18.1
Without beta blockersa 66 35.3 ± 7.6 1296 ± 702 99.3 ± 11.0 38.7 ± 8.4 748 ± 249 11860 ± 4447 96.6 ± 25.3
P value NS NS NS NS 0.091 0.122 NS
On diuretic∗ 8 40.3 ± 7.5 1439 ± 706 99.7 ± 8.9 35.2 ± 9.5 607 ± 83 13430 ± 2620 86.3 ± 10.5
Without diuretic∗ 66 34.9 ± 7.6 1264 ± 673 99.6 ± 10.8 39.1 ± 8.2 744 ± 252 11978 ± 4539 96.6 ± 26.0
P value NS NS NS NS NS NS NS
Abbreviations are: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers
aHypertensive only.
as an outcome measure in treatment trials for ADPKD.
These cross-sectional observations, however, need to
be validated by a prospective longitudinal follow-up
study.
The results also indicate that renal hemodynamic and
functional parameters discriminate between normoten-
sive and hypertensive ADPKD subjects, despite ad-
ministration of antihypertensive therapies. Statistically
nonsignificant trends toward higher RBF and lower RVR
were observed in subjects treated with ACE inhibitors,
angiotensin receptor blockers, or calcium channel block-
ers, whereas the reverse was true in those receiving beta
blockers or diuretics. Their interpretation should be ex-
tremely cautious, because of small sample sizes, simulta-
neous utilization of several antihypertensive agents in a
few patients, and variable durations of therapy. Never-
theless, they raise the possibility that measurements of
renal hemodynamic parameters by MR might help in the
selection or optimization of antihypertensive therapy in
ADPKD.
The higher volume of the left polycystic kidneys is not
entirely unexpected. The left kidney is slightly larger than
the right, 136 mL compared to 123 mL or 10% larger, as
measured by computed tomography in healthy subjects
[34] and previously reported in autopsy studies [35]. In the
present study, the left polycystic kidney is also approxi-
mately 10% larger than the right. However, the sever-
ity of the polycystic kidney disease in the left kidneys,
as reflected by higher cystic involvement, reduced RBF
and higher RVR, seems out of proportion to the rela-
tive increase in total kidney volume. This may suggest
that factors determining the difference in right and left
kidney volumes in normal individuals may also influence
the progression of the cystic disease. The left renal artery
originates from the aorta at a slightly higher level than the
right renal artery. In normal subjects, blood flow to the
left kidney is slightly higher than flow to the right kidney,
but renal perfusion, taking into account renal volumes,
is identical for both kidneys [34]. Nevertheless, it is pos-
sible that subtle developmental or hemodynamic differ-
ences between the kidneys could have an effect on the
progression of the disease.
RI measured by Doppler ultrasonography has been
frequently used to estimate RVR in renal allografts and
in native kidneys [36–39]. In one study of patients with
ADPKD, RI was found to correlate with morphologic and
functional indices of disease severity [40]. The present
study confirms that RI measured by MR correlates
with total kidney volume, cyst volume, and percent cyst
volume. However, the correlation was weaker than that
between RVR and renal volumes. In addition, RI was
similar in the right and left polycystic kidneys despite
significant differences in RVR. This is likely due to the
dependency of RI on other variables such as arterial com-
pliance and pulse pressure [41, 42].
CONCLUSION
This study shows that novel MR technologies allow a
real-time, noninvasive assessment of renal hemodynamic
parameters. The capability to accurately assess the renal
circulation by MR has great potential for investigation
of the role of hemodynamic alterations in renal disease
progression, not only in ADPKD, but also in other renal
diseases.
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